Real-world impact of empagliflozin on total cost of care in adults with type 2 diabetes: Results from an outcomes-based agreement

BACKGROUND: Value-based health care is expanding through payment models such as outcomes-based agreements between manufacturers and payers. OBJECTIVE: To describe the total-cost-of-care outcomes of an outcomes-based agreement evaluating the real-world impact of empagliflozin vs other type 2 diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales: Peasah, Samuel K, Huang, Yan, Palli, Swetha R, Swart, Elizabeth CS, Donato, Bonnie MK, Pimple, Pratik, Bovier, Jacqueline, Manolis, Chronis, Good, Chester B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387982/
https://www.ncbi.nlm.nih.gov/pubmed/36705285
http://dx.doi.org/10.18553/jmcp.2023.29.2.152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387982/
https://www.ncbi.nlm.nih.gov/pubmed/36705285
http://dx.doi.org/10.18553/jmcp.2023.29.2.152

Ejemplares similares